MedPath

Pertuzumab

Generic Name
Pertuzumab
Brand Names
Perjeta, Perjeta-Herceptin, Phesgo
Drug Type
Biotech
Chemical Formula
-
CAS Number
380610-27-5
Unique Ingredient Identifier
K16AIQ8CTM
Background

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.

Indication

Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.

Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.

Associated Conditions
Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
Associated Therapies
-

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2020-09-04
Last Posted Date
2024-12-13
Lead Sponsor
AstraZeneca
Target Recruit Count
245
Registration Number
NCT04538742
Locations
🇬🇧

Research Site, Buckhurst Hill, United Kingdom

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Phase 3
Conditions
Breast Cancer
Interventions
Drug: HS627
Drug: Pertuzumab
First Posted Date
2020-08-17
Last Posted Date
2020-08-17
Lead Sponsor
BioRay Pharmaceutical Co., Ltd.
Target Recruit Count
408
Registration Number
NCT04514419
Locations
🇨🇳

The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

MARGetuximab Or Trastuzumab (MARGOT)

Phase 2
Active, not recruiting
Conditions
HER2-positive Breast Cancer
Breast Cancer
Stage III Breast Cancer
Stage II Breast Cancer
Interventions
First Posted Date
2020-06-11
Last Posted Date
2024-10-02
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
174
Registration Number
NCT04425018
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Dana-Farber Brigham Cancer Center - Foxborough, Foxboro, Massachusetts, United States

and more 11 locations

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2
Suspended
Conditions
HER2-positive Breast Cancer
Interventions
First Posted Date
2020-06-05
Last Posted Date
2024-10-08
Lead Sponsor
University of Rochester
Target Recruit Count
20
Registration Number
NCT04419181
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer Invasive
Interventions
Drug: Pyrotinib
Drug: Trastuzumab
Drug: Nab-paclitaxel
Drug: Pertuzumab
Drug: Physician's choice
Drug: EC chemotherapy
Drug: T-DM1
Procedure: Surgery
First Posted Date
2020-05-22
Last Posted Date
2022-03-31
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
216
Registration Number
NCT04398914
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Phase 3
Not yet recruiting
Conditions
HER2-positive Breast Cancer
Interventions
First Posted Date
2020-04-08
Last Posted Date
2020-04-08
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
493
Registration Number
NCT04337658
Locations
🇨🇳

Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Phase 1
Recruiting
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2020-02-05
Last Posted Date
2023-04-18
Lead Sponsor
SOLTI Breast Cancer Research Group
Target Recruit Count
15
Registration Number
NCT04253561
Locations
🇪🇸

ICO Badalona, Badalona, Barcelona, Spain

🇪🇸

Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain

🇪🇸

Hospital Universitario del Vall d' Hebron, Barcelona, Spain

and more 7 locations

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Phase 3
Active, not recruiting
Conditions
Advanced HER2+Breast Cancer
Interventions
First Posted Date
2019-12-23
Last Posted Date
2025-01-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
19
Registration Number
NCT04208178
Locations
🇺🇸

Highlands Oncology Group, Fayetteville, Arkansas, United States

🇺🇸

University of California LA, Los Angeles, California, United States

🇪🇸

Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

First Posted Date
2019-12-10
Last Posted Date
2020-03-09
Lead Sponsor
Fudan University
Target Recruit Count
1560
Registration Number
NCT04193059
Locations
🇨🇳

Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Breast Cancer
Breast Cancer
Advanced Breast Cancer
Endometrial Cancer
Interventions
First Posted Date
2019-12-06
Last Posted Date
2024-08-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
500
Registration Number
NCT04188548
Locations
🇺🇸

Winship Cancer Center Emory University, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 69 locations
© Copyright 2025. All Rights Reserved by MedPath